
US FDA clearance enables first-in-human study of PTD802, a selective GPR17 antagonist Small molecule therapeutic designed to promote remyelination in neurological diseases such as multiple sclerosis Milestone supports Pheno Therapeutics’ clinical development strategy Edinburgh, UK, June 22, 2026 – Pheno…
Read More
